|
Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial. |
|
|
Research Funding - NanoString Technologies (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Honoraria - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech |
Research Funding - AB Science; Abbvie; Abraxis BioScience; Amgen; Asana Biosciences; Astellas Pharma; AstraZeneca; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Exelixis; GlaxoSmithKline; GlaxoSmithKline; ImClone Systems; LEO Pharma; Lilly; Medivation; Merck; Merrimack; Millennium; Mylan; Novartis; Pfizer; Roche/Genentech; Sanofi; Taiho Pharmaceutical |
|
|
Honoraria - Astellas Medivation; Pfizer; Roche |
Consulting or Advisory Role - Pfizer; Roche |
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer; Puma Biotechnology; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Puma Biotechnology |
Stock and Other Ownership Interests - Puma Biotechnology |
|
|
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche/Genentech |
Research Funding - Novartis (Inst); Roche (Inst) |